Skip to main content
SpringerLink
Log in

Major bleeding risk with anticoagulants in the real world

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Lip GYH, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: A "real-world" observational study in the United States. International Journal of Clinical Practice : 23 Aug 2016. Available from: URL: http://doi.org/10.1111/ijcp.12863

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Major bleeding risk with anticoagulants in the real world. Reactions Weekly 1618, 8 (2016). https://doi.org/10.1007/s40278-016-21013-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-21013-4

Search

Navigation